Market Cap
US$6.4b
Last Updated
2019/08/17 23:34 UTC
Data Sources
Company Financials +
Executive Summary
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
Snowflake
Fundamentals
Outstanding track record with adequate balance sheet.
Similar Companies
Share Price & News
How has Bruker's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.1%
NasdaqGS:BRKR
-0.5%
US Life Sciences
-1.0%
US Market
1 Year Return
21.3%
NasdaqGS:BRKR
10.4%
US Life Sciences
-0.4%
US Market
BRKR outperformed the Life Sciences industry which returned 10.4% over the past year.
BRKR outperformed the Market in United States of America which returned -0.4% over the past year.
Share holder returns
| BRKR | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.1% | -0.5% | -1.0% |
| 30 Day | -14.5% | -4.9% | -3.3% |
| 90 Day | 0.2% | 3.2% | 0.8% |
| 1 Year | 21.8%21.3% | 10.6%10.4% | 1.9%-0.4% |
| 3 Year | 91.3%88.2% | 70.1%68.7% | 39.4%30.4% |
| 5 Year | 110.4%106.4% | 110.3%100.3% | 54.2%37.1% |
Price Volatility Vs. Market
How volatile is Bruker's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
Does Bruker Corporation's (NASDAQ:BRKR) CEO Pay Compare Well With Peers?1 week ago | Simply Wall St
Does Bruker Corporation's (NASDAQ:BRKR) August Stock Price Reflect Its Future Growth?3 weeks ago | Simply Wall St
How To Take Advantage Of Bruker Corporation (NASDAQ:BRKR) In A Bear MarketValuation
Is Bruker undervalued based on future cash flows and its price relative to the stock market?
34.35x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Bruker's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Bruker's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Bruker is good value based on earnings compared to the US Life Sciences industry average.
Bruker is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Bruker is poor value based on expected growth next year.
Price Based on Value of Assets
Bruker is overvalued based on assets compared to the US Life Sciences industry average.
Next Steps
Future Growth
How is Bruker expected to perform in the next 1 to 3 years based on estimates from 12 analysts?
17.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Bruker's revenue is expected to grow by 5.3% yearly, however this is not considered high growth (20% yearly).
Bruker's earnings are expected to grow by 17.4% yearly, however this is not considered high growth (20% yearly).
Bruker's revenue growth is positive but not above the United States of America market average.
Bruker's earnings growth is expected to exceed the United States of America market average.
Bruker's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Bruker is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
Next Steps
Past Performance
How has Bruker performed over the past 5 years?
17.7%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Bruker's year on year earnings growth rate has been positive over the past 5 years.
Bruker's 1-year earnings growth exceeds its 5-year average (105.7% vs 17.7%)
Bruker's earnings growth has exceeded the US Life Sciences industry average in the past year (105.7% vs 45%).
Return on Equity
Bruker has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
Return on Assets
Bruker used its assets more efficiently than the US Life Sciences industry average last year based on Return on Assets.
Return on Capital Employed
Bruker has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Bruker's financial position?
Financial Position Analysis
Bruker is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Bruker's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Bruker's level of debt (55.4%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (40.2% vs 55.4% today).
Debt is well covered by operating cash flow (37.4%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 23.4x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 2.8x debt.
Next Steps
Dividend
What is Bruker's current dividend yield, its reliability and sustainability?
0.39%
Expected Dividend Yield
Upcoming Dividend Payment
Purchase Bruker before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield and Payments Analysis
Bruker's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.49%).
Bruker's dividend is below the markets top 25% of dividend payers in United States of America (3.84%).
Bruker is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
Bruker is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to Shareholders
No need to calculate the sustainability of Bruker's dividends as it is not paying a notable one for United States of America.
Future Payout to Shareholders
No need to calculate the sustainability of Bruker's dividends in 3 years as they are not expected to pay a notable one for United States of America.
Next Steps
Management
What is the CEO of Bruker's salary, the management and board of directors tenure and is there insider trading?
8.0yrs
Average management tenure
CEO
Frank Laukien (59yo)
28.5yrs
Tenure
US$4,479,899
Compensation
Dr. Frank H. Laukien, Ph.D., has been the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Executi ...
CEO Compensation Analysis
Frank's remuneration is lower than average for companies of similar size in United States of America.
Frank's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
8.0yrs
Average Tenure
61yo
Average Age
The average tenure for the Bruker management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
4.3yrs
Average Tenure
61.5yo
Average Age
The tenure for the Bruker board of directors is about average.
Insider Trading
Bruker individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chairman Chairman of the Board |
| Shares | 400,000 |
| Max Price | US$41.48 |
| Entity | Individual |
| Role | Chairman Chairman of the Board |
| Shares | 400,000 |
| Max Price | US$42.31 |
| Entity | Individual |
| Role | Member of the Board of Directors |
| Shares | 1,374 |
| Max Price | US$41.79 |
Ownership Breakdown
Management Team
Stacey Desrochers
Treasurer & Director of Investor Relations
Gerald Herman (61yo)
CFO, VP & Corporate Controller
- Tenure: 1.4yrs
- Compensation: $1.12m
Juergen Srega (64yo)
President of Bruker CALID Group & Bruker Daltonics Division
- Tenure: 6.6yrs
- Compensation: $1.39m
Miroslava Minkova
Director of Investor Relations & Corporate Development
Frank Laukien (59yo)
Chairman
- Tenure: 28.5yrs
- Compensation: $4.48m
Falko Busse (52yo)
Executive Officer
- Tenure: 1.3yrs
- Compensation: $1.38m
Richard Stein (67yo)
Secretary
- Tenure: 19.6yrs
- Compensation: $16.00k
Collin D’Silva (62yo)
President of Chemical Analysis Division
- Tenure: 9.3yrs
- Compensation: $1.10m
Mark Munch (57yo)
Executive VP and President of Bruker Nano Group & Bruker Nano Surfaces Division
- Tenure: 4.1yrs
- Compensation: $1.82m
Urban Faeh
President of Bruker Optics Division
- Tenure: 9.6yrs
Board Members
William Linton (71yo)
Lead Director
- Tenure: 15.4yrs
- Compensation: $198.03k
Cynthia Friend (64yo)
Director
- Tenure: 3.3yrs
- Compensation: $190.15k
Marc Kastner (73yo)
Director
- Tenure: 4.6yrs
- Compensation: $191.87k
Adelene Perkins (59yo)
Director
- Tenure: 2.3yrs
- Compensation: $200.78k
Gilles Martin (56yo)
Director
- Tenure: 5.6yrs
- Compensation: $185.03k
Frank Laukien (59yo)
Chairman
- Tenure: 28.5yrs
- Compensation: $4.48m
Bob Rosenthal (62yo)
Director
- Tenure: 3.8yrs
- Compensation: $203.03k
Richard Packer (61yo)
Independent Director
- Tenure: 12.3yrs
- Compensation: $215.60k
Hermann Requardt (64yo)
Director
- Tenure: 4.0yrs
- Compensation: $193.03k
John Ornell (61yo)
Director
- Tenure: 4.0yrs
- Compensation: $218.03k
Company Information
Bruker Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bruker Corporation
- Ticker: BRKR
- Exchange: NasdaqGS
- Founded: 1991
- Industry: life sciences tools and services
- Sector: pharmaceuticals & biotech
- Market Cap: US$6.413b
- Shares outstanding: 154.64m
- Website: Click here
Number of Employees
Location
- Bruker Corporation
- 40 Manning Road
- Billerica
- Massachusetts
- 1821
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BRKR | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Aug 2000 |
| BKD | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Aug 2000 |
| BRKR * | BMV (Bolsa Mexicana de Valores) | Yes | Common Shares | MX | MXN | Aug 2000 |
Biography
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/08/17 23:34 |
| End of Day Share Price | 2019/08/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.